Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study

被引：0
|
作者：
Han, P. [1 ]
Huang, X. [1 ]
Liang, F. [1 ]
Lin, P. [1 ]
Chen, R. [1 ]
Wu, T. [1 ]
Li, Y. [1 ]
机构：
[1] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Otorhinolaryngol Head & Neck Surg, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.920
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
858P
引用
收藏
页码：S619 / S619
页数：1
相关论文
共 50 条
  • [41] CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial
    Liu, Fangqi
    Yang, Li
    Wu, Yuchen
    Li, Cong
    Zhao, Jiang
    Keranmu, Adili
    Zheng, Hongtu
    Huang, Dan
    Wang, Lei
    Tong, Tong
    Xu, Junyan
    Zhu, Ji
    Cai, Sanjun
    Xu, Ye
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (06) : 589 - 597
  • [42] Neoadjuvant immunochemotherapy for locally advanced hypopharyngeal squamous cell carcinoma: Pooled results analysis from two prospective single-arm phase 2 trials
    Gui, Lin
    Xie, Zucheng
    Wang, Xiaolei
    Liu, Shaoyan
    Yi, Junlin
    An, Changming
    Chen, Xinrui
    Shi, Yuankai
    He, Xiaohui
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] A prospective phase II study of induction chemotherapy and nimotuzumab for resectable locally advanced head and neck squamous cell carcinoma.
    Zhao, Xiaoying
    Guo, Ye
    Zhu, Yongxue
    Wang, Yu
    Zhu, Guopei
    Hu, Chaosu
    Ji, Qinghai
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [44] Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck
    Maguire, Patrick D.
    Neal, Charles R.
    Hardy, Stuart M.
    Schreiber, Andrew M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1210 - 1216
  • [45] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
    Kim, JG
    Sohn, SK
    Kim, DH
    Baek, JH
    Jeon, SB
    Chae, YS
    Lee, KB
    Park, JS
    Sohn, JH
    Kim, JC
    Park, IK
    BRITISH JOURNAL OF CANCER, 2005, 93 (10) : 1117 - 1121
  • [46] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
    Kim, J. G.
    Kim, D. H.
    Sohn, S. K.
    Baek, J. H.
    Chae, Y. S.
    Lee, K. B.
    Sohn, J. H.
    Park, J. S.
    Kim, J. C.
    Park, I. K.
    EJC SUPPLEMENTS, 2005, 3 (02): : 300 - 300
  • [47] Phase II study of concurrent chemoradiotherapy with capecitabine and cisplatin in patients with locally advanced squamous cell carcinoma of the head and neck
    J G Kim
    S K Sohn
    D H Kim
    J H Baek
    S B Jeon
    Y S Chae
    K B Lee
    J S Park
    J H Sohn
    J C Kim
    I K Park
    British Journal of Cancer, 2005, 93 : 1117 - 1121
  • [48] A prospective phase 2 single-arm study to evaluate the efficacy and safety of neoadjuvant pembrolizumab plus chemotherapy in patients with locally advanced esophageal squamous cell carcinoma (Keypoint-1)
    Xu, Peiran
    Su, Polan
    Wang, Weiwei
    He, Jia
    Zhao, Luo
    Zhou, Weixun
    Merritt, Robert
    Li, Li
    He, Kai
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [49] Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck
    Faivre, S
    Marti, A
    Rixe, O
    Janot, F
    Julieron, M
    Gatineau, M
    Temam, S
    Armand, JP
    Domenge, C
    Luboinski, B
    Raymond, E
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2005, 27 (04): : 311 - 319
  • [50] Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study
    Zhao, Jinbo
    Yan, Xiaolong
    Bai, Yuquan
    Duan, Hongtao
    Jiang, Tao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345